Patents by Inventor James W. Larrick

James W. Larrick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS
    Publication number: 20230130425
    Abstract: The present disclosure provides adamantyl compounds having one or more amine groups and one or more nitrate groups. The aminoadamantyl nitrate compounds can be used to treat disorders of the central nervous system, including neurodegenerative and non-neurodegenerative diseases.
    Type: Application
    Filed: September 19, 2022
    Publication date: April 27, 2023
    Inventors: Cyrus K. BECKER, Meenakshi S. VENKATRAMAN, Xiaoming ZHANG, James W. LARRICK
  • Aminoadamantyl nitrate compounds and their use to treat CNS disorders
    Patent number: 11447442
    Abstract: The present disclosure provides adamantyl compounds having one or more amine groups and one or more nitrate groups. The aminoadamantyl nitrate compounds can be used to treat disorders of the central nervous system, including neurodegenerative and non-neurodegenerative diseases.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: September 20, 2022
    Assignee: Panorama Research, Inc.
    Inventors: Cyrus K. Becker, Meenakshi S. Venkatraman, Xiaoming Zhang, James W. Larrick
  • Use of NK-1 receptor antagonist serlopitant in pruritus
    Patent number: 11026920
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: June 8, 2021
    Assignee: VYNE THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS
    Publication number: 20200377444
    Abstract: The present disclosure provides adamantyl compounds having one or more amine groups and one or more nitrate groups. The aminoadamantyl nitrate compounds can be used to treat disorders of the central nervous system, including neurodegenerative and non-neurodegenerative diseases.
    Type: Application
    Filed: November 20, 2018
    Publication date: December 3, 2020
    Inventors: Cyrus K. BECKER, Meenakshi S. VENKATRAMAN, Xiaoming ZHANG, James W. LARRICK
  • Anti-Marinobufagenin Antibodies and Uses Thereof
    Publication number: 20200347129
    Abstract: The present disclosure provides chimeric, humanized and human monoclonal antibodies (mAbs) and fragments thereof that specifically bind to marinobufagenin (MBG) with high affinity. The anti-MBG mAbs and fragments thereof can be used to treat MBG-associated disorders, including hypertensive disorders and fibrotic disorders, optionally in combination with an additional therapeutic agent. Furthermore, the anti-MBG mAbs and fragments thereof can be used for diagnostic purposes, including to detect MBG in biological samples and to diagnose MBG-associated disorders.
    Type: Application
    Filed: May 8, 2020
    Publication date: November 5, 2020
    Applicant: CTS Biopharma LLC
    Inventors: James W. Larrick, John M. Wages, Andrew R. Mendelsohn, Vikram Sharma, Bo Yu
  • USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS
    Publication number: 20200306224
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: March 2, 2020
    Publication date: October 1, 2020
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • Use of NK-1 receptor antagonists in pruritus
    Patent number: 10702499
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: July 7, 2020
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Anti-marinobufagenin antibodies and uses thereof
    Patent number: 10654925
    Abstract: The present disclosure provides chimeric, humanized and human monoclonal antibodies (mAbs) and fragments thereof that specifically bind to marinobufagenin (MBG) with high affinity. The anti-MBG mAbs and fragments thereof can be used to treat MBG-associated disorders, including hypertensive disorders and fibrotic disorders, optionally in combination with an additional therapeutic agent. Furthermore, the anti-MBG mAbs and fragments thereof can be used for diagnostic purposes, including to detect MBG in biological samples and to diagnose MBG-associated disorders.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: May 19, 2020
    Assignee: CTS Biopharma LLC
    Inventors: James W. Larrick, John M. Wages, Andrew R. Mendelsohn, Vikram Sharma, Bo Yu
  • Use of NK-1 receptor antagonist serlopitant in pruritus
    Patent number: 10617671
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: April 14, 2020
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS
    Publication number: 20200054604
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: March 25, 2019
    Publication date: February 20, 2020
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS
    Publication number: 20200054603
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: March 25, 2019
    Publication date: February 20, 2020
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • Anti-Marinobufagenin Antibodies and Uses Thereof
    Publication number: 20190389947
    Abstract: The present disclosure provides chimeric, humanized and human monoclonal antibodies (mAbs) and fragments thereof that specifically bind to marinobufagenin (MBG) with high affinity. The anti-MBG mAbs and fragments thereof can be used to treat MBG-associated disorders, including hypertensive disorders and fibrotic disorders, optionally in combination with an additional therapeutic agent. Furthermore, the anti-MBG mAbs and fragments thereof can be used for diagnostic purposes, including to detect MBG in biological samples and to diagnose MBG-associated disorders.
    Type: Application
    Filed: June 20, 2019
    Publication date: December 26, 2019
    Applicant: CTS Biopharma LLC
    Inventors: James W. Larrick, John M. Wages, Andrew R. Mendelsohn, Vikram Sharma, Bo Yu
  • Use of NK-1 receptor antagonists in pruritus
    Patent number: 10278952
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: May 7, 2019
    Assignee: Menlo Therapeutics Inc.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Use of NK-1 receptor antagonist serlopitant in pruritus
    Patent number: 10278953
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: May 7, 2019
    Assignee: Menlo Therapeutics Inc.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • COMPOSITIONS AND METHODS FOR TISSUE REPAIR
    Publication number: 20190125891
    Abstract: The present invention provides compositions and methods for targeting an extracellular matrix derived (EMD) peptide predominantly to an injured tissue, as opposed to an uninjured tissue in vivo. The targeted EMD peptide facilitates the repair and/or regeneration of the injured tissue by providing a surface for cells to attach and grow, thereby facilitating the repair and/or regeneration of the injured tissue.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 2, 2019
    Inventors: Randall J. Lee, Shirley Mihardja, Manley Huang, James W. Larrick
  • USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS
    Publication number: 20180325866
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: April 10, 2018
    Publication date: November 15, 2018
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS
    Publication number: 20180325867
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: April 18, 2018
    Publication date: November 15, 2018
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • Use of NK-1 receptor antagonist serlopitant in pruritus
    Patent number: 9974769
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: May 22, 2018
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Use of NK-1 receptor antagonists in pruritus
    Patent number: 9968588
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: May 15, 2018
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS
    Publication number: 20170348283
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: June 16, 2017
    Publication date: December 7, 2017
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK